From the Analyst's Couch

The antibody–drug conjugate landscape

• Patrick Flynn
• Smruthi Suryaprakash
• John Wu

The colorectal cancer drug market

• Laura Ramos García
• Rachel M. Webster

The pipeline and market for psoriasis drugs

• Rami Al-Horani
• Thomas Chui
• Bashar Hamad

Biopharma dealmaking in 2023

• Patricia Giglio
• Amanda Micklus

The landscape and market for HIV therapies

• Zachery G. Bowe
• Shiva Shanmugam
• Steven I. Gubernick

The renal cell carcinoma drug market

• Joan Tur
• Rachel M. Webster

The pipeline and market for migraine drugs

• Kritika Chaudhari
• Basharut A. Syed

Trends in rare disease drug development

• Rui Chen
• Sen Liu
• Shuyang Zhang

The company landscape for artificial intelligence in large-molecule drug discovery

• Navraj S. Nagra
• Lieven van der Veken
• Matej Macak

The R&D landscape for infectious disease vaccines

• Jianying Yue
• Yuehua Liu
• Wannian Liang

Investigating the origins of recent pharmaceutical innovation

• Alexander Schuhmacher
• Markus Hinder
• Dominik Hartl

Genomic medicines: the coming waves?

• Wen Xie
• Baiping Chen
• John Wong

Herding in the drug development pipeline

• Christian Fougner
• Julie Cannon
• Olivier Leclerc

First-in-class versus best-in-class: an update for new market dynamics

• Lindsay Spring
• Kunle Demuren
• John Wu

Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors

• Ana Rosa Saez-Ibanez
• Samik Upadhaya
• Jay Campbell

The non-small-cell lung cancer drug market

• Khurram Nawaz
• Rachel M. Webster

Biopharma dealmaking in 2022

• Patricia Giglio
• Amanda Micklus

The landscape for lipid-nanoparticle-based genomic medicines

• Malvika Verma
• Imran Ozer
• Michael Choy

The significance of blockbusters in the pharmaceutical industry

• Alexander Schuhmacher
• Markus Hinder
• Oliver Gassmann

Innovation in the Chinese pharmaceutical industry

• Linghui Kong
• Qiu Li
• Liming Shao